Details for New Drug Application (NDA): 074654
✉ Email this page to a colleague
NDA 074654 describes ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, which is a drug marketed by Sandoz and Stevens J and is included in two NDAs. It is available from one supplier. Additional details are available on the ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE profile page.
The generic ingredient in ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is aspirin; caffeine; orphenadrine citrate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
The generic ingredient in ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is aspirin; caffeine; orphenadrine citrate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
Summary for 074654
| Tradename: | ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE |
| Applicant: | Sandoz |
| Ingredient: | aspirin; caffeine; orphenadrine citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 385MG;30MG;25MG | ||||
| Approval Date: | Dec 31, 1996 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 770MG;60MG;50MG | ||||
| Approval Date: | Dec 31, 1996 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
